Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Ryota Tabei is active.

Publication


Featured researches published by Ryota Tabei.


Stem Cells Translational Medicine | 2014

A Massive Suspension Culture System With Metabolic Purification for Human Pluripotent Stem Cell-Derived Cardiomyocytes

Natsuko Hemmi; Shugo Tohyama; Kazuaki Nakajima; Hideaki Kanazawa; Tomoyuki Suzuki; Fumiyuki Hattori; Tomohisa Seki; Yoshikazu Kishino; Akinori Hirano; Marina Okada; Ryota Tabei; Rei Ohno; Chihana Fujita; Tomoko Haruna; Shinsuke Yuasa; Motoaki Sano; Jun Fujita; Keiichi Fukuda

Cardiac regenerative therapy with human pluripotent stem cells (hPSCs), such as human embryonic stem cells and induced pluripotent stem cells, has been hampered by the lack of efficient strategies for expanding functional cardiomyocytes (CMs) to clinically relevant numbers. The development of the massive suspension culture system (MSCS) has shed light on this critical issue, although it remains unclear how hPSCs could differentiate into functional CMs using a MSCS. The proliferative rate of differentiating hPSCs in the MSCS was equivalent to that in suspension cultures using nonadherent culture dishes, although the MSCS provided more homogeneous embryoid bodies (EBs), eventually reducing apoptosis. However, pluripotent markers such as Oct3/4 and Tra‐1‐60 were still expressed in EBs 2 weeks after differentiation, even in the MSCS. The remaining undifferentiated stem cells in such cultures could retain a strong potential for teratoma formation, which is the worst scenario for clinical applications of hPSC‐derived CMs. The metabolic purification of CMs in glucose‐depleted and lactate‐enriched medium successfully eliminated the residual undifferentiated stem cells, resulting in a refined hPSC‐derived CM population. In colony formation assays, no Tra‐1‐60‐positive colonies appeared after purification. The nonpurified CMs in the MSCS produced teratomas at a rate of 60%. However, purified CMs never induced teratomas, and enriched CMs showed proper electrophysiological properties and calcium transients. Overall, the combination of a MSCS and metabolic selection is a highly effective and practical approach to purify and enrich massive numbers of functional CMs and provides an essential technique for cardiac regenerative therapy with hPSC‐derived CMs.


PLOS ONE | 2015

Gelatin Hydrogel Enhances the Engraftment of Transplanted Cardiomyocytes and Angiogenesis to Ameliorate Cardiac Function after Myocardial Infarction

Kazuaki Nakajima; Jun Fujita; Makoto Matsui; Shugo Tohyama; Noriko Tamura; Hideaki Kanazawa; Tomohisa Seki; Yoshikazu Kishino; Akinori Hirano; Marina Okada; Ryota Tabei; Motoaki Sano; Shinya Goto; Yasuhiko Tabata; Keiichi Fukuda

Cell transplantation therapy will mean a breakthrough in resolving the donor shortage in cardiac transplantation. Cardiomyocyte (CM) transplantation, however, has been relatively inefficient in restoring cardiac function after myocardial infarction (MI) due to low engraftment of transplanted CM. In order to ameliorate engraftment of CM, the novel transplantation strategy must be invented. Gelatin hydrogel (GH) is a biodegradable water-soluble polymer gel. Gelatin is made of collagen. Although we observed that collagen strongly induced the aggregation of platelets to potentially cause coronary microembolization, GH did not enhance thrombogenicity. Therefore, GH is a suitable biomaterial in the cell therapy after heart failure. To assess the effect of GH on the improvement of cardiac function, fetal rat CM (5×106 or 1x106 cells) were transplanted with GH (10 mg/ml) to infarcted hearts. We compared this group with sham operated rats, CM in phosphate buffered saline (PBS), only PBS, and only GH-transplanted groups. Three weeks after transplantation, cardiac function was evaluated by echocardiography. The echocardiography confirmed that transplantation of 5×106 CM with GH significantly improved cardiac systolic function, compared with the CM+PBS group (fractional area change: 75.1±3.4% vs. 60.7±5.9%, p<0.05), only PBS, and only GH groups (60.1±6.5%, 65.0±2.8%, p<0.05). Pathological analyses demonstrated that in the CM+GH group, CM were efficiently engrafted in infarcted myocardium (p<0.01) and angiogenesis was significantly enhanced (p<0.05) in both central and peripheral areas of the scar. Moreover, quantitative RT-PCR revealed that angiogenic cytokines, such as basic fibroblast growth factor, vascular endothelial growth factor, and hepatocyte growth factor, were significantly enriched in the CM+GH group (p<0.05). Here, we report that GH confined the CM effectively in infarcted myocardium after transplantation, and that CM transplanted with GH improved cardiac function with a direct contraction effect and enhanced angiogenesis.


PLOS ONE | 2014

Derivation of transgene-free human induced pluripotent stem cells from human peripheral T cells in defined culture conditions.

Yoshikazu Kishino; Tomohisa Seki; Jun Fujita; Shinsuke Yuasa; Shugo Tohyama; Akira Kunitomi; Ryota Tabei; Kazuaki Nakajima; Marina Okada; Akinori Hirano; Hideaki Kanazawa; Keiichi Fukuda

Recently, induced pluripotent stem cells (iPSCs) were established as promising cell sources for revolutionary regenerative therapies. The initial culture system used for iPSC generation needed fetal calf serum in the culture medium and mouse embryonic fibroblast as a feeder layer, both of which could possibly transfer unknown exogenous antigens and pathogens into the iPSC population. Therefore, the development of culture systems designed to minimize such potential risks has become increasingly vital for future applications of iPSCs for clinical use. On another front, although donor cell types for generating iPSCs are wide-ranging, T cells have attracted attention as unique cell sources for iPSCs generation because T cell-derived iPSCs (TiPSCs) have a unique monoclonal T cell receptor genomic rearrangement that enables their differentiation into antigen-specific T cells, which can be applied to novel immunotherapies. In the present study, we generated transgene-free human TiPSCs using a combination of activated human T cells and Sendai virus under defined culture conditions. These TiPSCs expressed pluripotent markers by quantitative PCR and immunostaining, had a normal karyotype, and were capable of differentiating into cells from all three germ layers. This method of TiPSCs generation is more suitable for the therapeutic application of iPSC technology because it lowers the risks associated with the presence of undefined, animal-derived feeder cells and serum. Therefore this work will lead to establishment of safer iPSCs and extended clinical application.


International Journal of Cardiology | 2014

Successful second attempt multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation for an octogenarian with hypertrophic obstructive cardiomyopathy.

Yuichiro Maekawa; Masahiro Jinzaki; Atsushi Anzai; Hikaru Tsuruta; Keisuke Matsumura; Yoshitake Yamada; Ryota Tabei; Takashi Kawakami; Kentaro Hayashida; Shinsuke Yuasa; Mitsushige Murata; Masahiro Suzuki; Sachio Kuribayashi; Keiichi Fukuda

Successful second attempt multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation for an octogenarian with hypertrophic obstructive cardiomyopathy Yuichiro Maekawa ⁎, Masahiro Jinzaki , Atsushi Anzai , Hikaru Tsuruta , Keisuke Matsumura , Yoshitake Yamada , Ryota Tabei , Takashi Kawakami , Kentaro Hayashida , Shinsuke Yuasa , Mitsushige Murata , Masahiro Suzuki , Sachio Kuribayashi , Keiichi Fukuda a


PLOS ONE | 2015

The Prevalence of Clinically Significant Ischemia in Patients Undergoing Percutaneous Coronary Intervention: A Report from the Multicenter Registry

Jun Fujita; Shun Kohsaka; Ikuko Ueda; Taku Inohara; Yuichiro Maekawa; Akio Kawamura; Hideaki Kanazawa; Kentaro Hayashida; Ryota Tabei; Shugo Tohyama; Tomohisa Seki; Masahiro Suzuki; Motoaki Sano; Keiichi Fukuda

Background Myocardial perfusion scintigraphy (MPS) plays an important role in the evaluation and quantification of myocardial ischemia, and those with significant ischemia (SI) benefit most from revascularization procedures. This study aimed to identify the clinical factors and anatomical features associated with SI in patients with stable ischemic heart disease (SIHD). Methods and Results Data were analyzed from 4197 SIHD patients undergoing percutaneous coronary intervention (PCI). Ischemia was based on MPS findings prior to PCI, with SI defined as an ischemic region of more than 10% of the total left ventricular area. Logistic regression analysis was performed to identify any clinical factors associated with SI. MPS was used to evaluate 1070 (25.5%) patients pre-procedurally. Patients with a history of heart failure, stroke, or anginal symptoms with Canadian Cardiovascular Society class 2 or more were more likely to have SI (odds ratio [OR] 1.63, p = 0.025, OR: 1.85, p = 0.009, and OR: 1.49, p = 0.003, respectively). When angiographic variables were considered, a proximal left anterior descending artery (pLAD) lesion was the sole factor associated with SI (OR: 1.45, p = 0.012). Importantly, those with SI had more in-hospital complications (p = 0.006), most notably post-PCI infarcts (p = 0.008). Conclusions Patients’ background data, such as stronger anginal symptoms or a pLAD lesion, were associated with SI. Patients with SI must be treated with PCI to improve their long-term prognosis; however, procedure-related complications happen more frequently in SI patients than in non-SI patients. Physicians must give their full attention when performing the PCI procedure in SI patients to minimize their complication rate.


Internal Medicine | 2018

Recent Inferior Myocardial Infarction Complicated with a Right Ventricular Thrombus Detected by Three Cardiac Imaging Modalities

Toshiki Kuno; Syohei Imaeda; Kenji Hashimoto; Toshinobu Ryuzaki; Tetsuya Saito; Hiroyuki Yamazaki; Ryota Tabei; Masaki Kodaira; Manabu Hase; Yohei Numasawa

We report the case of a 71-year-old woman diagnosed with recent inferior myocardial infarction complicated with right ventricular infarction and a right ventricular thrombus. Three-dimensional transthoracic echocardiography, contrast-enhanced computed tomography, and cardiac magnetic resonance imaging clearly detected a thrombus. We consider cases with a recent right ventricular infarction to require assessment for thrombus formations in the right ventricle. Fortunately, vigorous anticoagulation therapy resolved the thrombi in both the right ventricle and right coronary artery.


Circulation | 2018

Pathological Findings of Rivaroxaban-Associated Hemorrhagic Pericarditis

Masaki Kodaira; Hiroyuki Yamazaki; Ryota Tabei; Toshiki Kuno; Kazuhiko Shimizu; Yohei Numasawa

Received January 22, 2018; revised manuscript received March 16, 2018; accepted April 4, 2018; released online May 16, 2018 Time for primary review: 29 days Department of Cardiology (M.K., H.Y., R.T., T.K.), Department of Pathology (K.S., Y.N.), Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan Mailing address: Masaki Kodaira, MD, PhD, Department of Cardiology, Japanese Red Cross Ashikaga Hospital, 284-1 Yobe-cho, Ashikaga 326-0843, Japan. E-mail: [email protected] ISSN-1346-9843 All rights are reserved to the Japanese Circulation Society. For permissions, please e-mail: [email protected] Pathological Findings of Rivaroxaban-Associated Hemorrhagic Pericarditis


Translational Medicine Communications | 2017

Cryoinjury-induced acute myocardial infarction model and ameroid constrictor-induced ischemic heart disease model in adult micro-mini pigs for preclinical studies

Akinori Hirano; Jun Fujita; Hideaki Kanazawa; Shinji Kawaguchi; Noriko Handa; Yoshitake Yamada; Shigeo Okuda; Shuji Hishikawa; Takumi Teratani; Satoshi Kunita; Shugo Tohyama; Tomohisa Seki; Ryota Tabei; Kazuaki Nakajima; Yoshikazu Kishino; Marina Okada; Kazuma Okamoto; Hideyuki Shimizu; Eiji Kobayashi; Keiichi Fukuda


Circulation | 2017

Abstract 16120: Development of a Transplant Injection Device for the Optimal Distribution and Retention of iPS Cell-Derived Cardiomyocytes

Ryota Tabei; Hideaki Kanazawa; Jun Fujita; Shugo Tohyama; Akinori Hirano; Shinji Kawaguchi; Kazuaki Nakajima; Tomohisa Seki; Yoshikazu Kishino; Marina Okada; Hideyuki Shimizu; Eiji Kobayashi; Yasuhiko Tabata; Keiichi Fukuda


Cardiovascular Intervention and Therapeutics Japanese Edition | 2016

A Case with Intractable ST-Elevation Myocardial Infarction Complicated with Acute Stent Thrombosis

Hiromu Hase; Hiroyuki Yamazaki; Ryota Tabei; Toshiki Kuno; Masaki Kodaira; Hiroyuki Motoda; Yohei Numasawa

Collaboration


Dive into the Ryota Tabei's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge